Neurobiology of Depression

Road to Novel Therapeutics

1st Edition - January 3, 2019
Editors: Joao Quevedo, Andre Ferrer Carvalho, Carlos A. Zarate
Language: English
Paperback ISBN:
9 7 8 - 0 - 1 2 - 8 1 3 3 3 3 - 0
eBook ISBN:
9 7 8 - 0 - 1 2 - 8 1 3 3 3 4 - 7

Neurobiology of Depression: Road to Novel Therapeutics synthesizes the basic neurobiology of major depressive disorder with discussions on the most recent advances in research,… Read more

Purchase options

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

Resources

Textbook support for instructors(opens in new tab/window)

Neurobiology of Depression: Road to Novel Therapeutics synthesizes the basic neurobiology of major depressive disorder with discussions on the most recent advances in research, including the interacting pathways implicated in the pathophysiology of MDD, omics technologies, genetic approaches, and the development of novel optogenetic approaches that are changing research perspectives and revolutionizing research into depression. These basic foundational understandings on the neurobiology underlying the disorder, along with a comprehensive summary of the most recent advances in research are combined in this book to aid advanced students and researchers in their understanding of MDD.

Depression is one of the most common mental-health disorders caused by a variety of genetic, biological, environmental and psychological factors. Major depressive disorder (MDD) is typically treated with first-line antidepressant agents that primarily target monoamine neurotransmission. However, only approximately one-third of patients with MDD achieve remission following a trial with such an antidepressant. Furthermore, MDD is a heterogeneous phenotype, and new frameworks, such as the NIMH Research Domain Criteria (RDoC) may provide a more accurate, biologically based comprehension of the symptomatic heterogeneity of this devastating illness.

1. The Classification of Depression: Embracing Phenotypic Heterogeneity in the Era of the RDoC
Elizabeth D. Ballard, Ioline D. Henter and Carlos A. Zarate, Jr.

2. The Role of Environmental and Psychosocial Factors in Depression
Gordon Parker

3. Gene-Environment Interactions and Epigenetic Mechanisms in Depression
Magdalene C. Jawahar, Catherine G. Toben and Bernhard T. Baune

4. Pathophysiology of Cognitive Impairment in Depression
Christopher R. Bowie, Melissa Milanovic and Tanya Tran

5. Anhedonia in Depression: Mechanisms, Assessment, and Therapeutics
Theodore P. Beauchaine, Daniel N. Klein, Erin Knapton and Aimee Zisner

6. The Neurotrophic Hypothesis of Depression Revisited: New Insights and Therapeutic Implications
Minal Jaggar, Sashaina E. Fanibunda, Shreya Ghosh, Ronald S. Duman and Vidita A. Vaidya

8. Neuro-Immune Interactions in Depression: Mechanisms and Translational Implications
Helena M. Abelaira, Ritele H. Silva, Anelise S. Carlessi, João Quevedo and Gislaine Z. Réus

9. The Hypothalamic-Pituitary-Adrenal Axis in Depression: Molecular Regulation, Pathophysiological Role, and Translational Implications
Theo Rein, Oliver Ambrée, Gabriel R. Fries, Virginie Rappeneau, Ulrike Schmidt and Chadi Touma

10. Intracellular Signaling Pathways Implicated in the Pathophysiology of Depression
Gislaine Z. Réus, Jaqueline S. Generoso, Ana Lúcia S. Rodrigues and João Quevedo

11. The Long-Lasting Neurobiological Scars of Early-Life Stress: Implications for the Neurobiology of Depression
Mousa Botros, Gabrielle Hodgins and Charles B. Nemeroff

12. Molecular, Cellular, and Circuit Basis of Depression Susceptibility and Resilience
Ming-Hu Han, Scott J. Russo and Eric J. Nestler

13. More Than a Gut Feeling: Emerging Roles of the Microbiome in the Pathophysiology and Treatment of Depression
Jane A. Foster

14. Optogenetics: Illuminating the Neural Circuits of Depression
Muir J. and Bagot R.C.

15. Mitochondrial Dysfunction and Oxidative Stress: Relevance to the Pathophysiology and Treatment of Depression
Adrian L. Lopresti

16. Obesity and Depression: Shared Pathophysiology and Translational Implications
Lison Huet, Ines Delgado, Bruno Aouizerate, Nathalie Castanon and Lucile Capuron

17. Depression and Cardiovascular Risk: Epidemiology, Mechanisms, and Implications
Jessica Hatch and Benjamin I. Goldstein

18. Poststroke Depression: Pathophysiology and Treatment Strategies
Yun-Ju Lai and Louise D. McCullough

19. Is Depression Associated With Accelerated Aging? Mechanisms and Implications
Daniel Lindqvist, Naomi M. Simon and Owen M. Wolkowitz

20. Relationship Between Complicated Grief and Depression: Relevance, Etiological Mechanisms, and Implications
Nicole J. LeBlanc, Naomi M. Simon, Charles F. Reynolds, III, M. Katherine Shear, Natalia Skritskaya and Sidney Zisook

21. A Neural Circuit-Based Model for Depression Anchored in a Synthesis
of Insights From Functional Neuroimaging
Andrea N. Goldstein-Piekarski and Leanne M. Williams

22. Could Depression be Preventable? Evidence and Perspectives
Scott B. Patten

23. Treating Depression in the Era of Precision Medicine: Challenges and Perspectives
Michael Musker and Ma-Li Wong

24. Neurobiological Aspects of Functional Recovery in Major Depressive Disorder
Trisha Chakrabarty, David Sarfati and Raymond W. Lam

25. Diet and Depression: From Epidemiology to Novel Therapeutics
Wolfgang Marx, Erin Hoare and Felice Jacka

26. Physical Activity and Exercise as a Treatment of Depression: Evidence and Neurobiological Mechanism
Brendon Stubbs and Felipe Schuch

27. Antidepressants and Suicidality—
Controversies and Possible Mechanisms
Josef Witt-Doerring and Sanjay Mathew

28. Altered GABAergic Function, Cortical Microcircuitry, and Information Processing in Depression
Dwight F. Newton, Corey Fee, Yuliya S. Nikolova and Etienne Sibille

29. Biomarker-Based Treatment Selection: A Precision Medicine Approach for Depression
Jennifer L. Furman and Madhukar H. Trivedi

30. Implications of Pharmacogenomics in Depression Pathophysiology and Treatment
Forbes M.P., Jaksa P., Eyre H.A. and Bousman C.

31. Novel Neuromodulatory Approaches for Depression: Neurobiological Mechanisms
Lucia Bulubas, Eva Mezger, Daniel Keeser, Frank Padberg and Andre R. Brunoni

32. Electroconvulsive Therapy for Depression: Neurobiological Mechanisms
Peter Mulders, Stevie Jaarsveld, Indira Tendolkar and Philip van Eijndhoven

33. Deep Brain Stimulation: Mechanisms Underpinning Antidepressant Effects
Sonia Torres-Sanchez, Laura Perez-Caballero and Esther Berrocoso

34. Novel Therapeutic Targets for Major Depressive Disorder
Max A. Lazar and Roger S. McIntyre

35. The Search for Rapid Acting Antidepressants: Research Synthesis and Perspectives
Gerard Sanacora, Brandon M. Kitay and Samuel T. Wilkinson

36. Pediatric Depression
Frances Rice and Naomi Warne

37. Depression in Women
Molly M. Hyer and Gretchen N. Neigh

38. Advances in the Neurobiology of Late-Life Depression
Breno Satler Diniz and Antonio Lucio Teixeira

Joao Quevedo

Dr. João Luciano de Quevedo, MD, PhD, is a Professor of Psychiatry at the McGovern Medical School, the University of Texas Health Science Center at Houston, where he is the Vice-Chair for Faculty Development and Outreach, Director of the Translational Psychiatry Program, and Director of the Treatment-Resistant Depression Clinic. Before moving to Houston, he was a Dean at the University of Southern Santa Catarina Medical School, Criciúma, SC, Brazil, where he is still an Adjunct Professor of Psychiatry. He is also Editor-in-Chief of the Brazilian Journal of Psychiatry and Director of the Continuous Medical Education Program in Psychiatry (PROPSIQ) of the Brazilian Psychiatric Association. Dr. Quevedo’s research interest is neurobiology of psychiatric disorders, particularly mood disorders, and he is a specialist in both unipolar and bipolar treatment–resistant depression. He is author of nearly 600 publications and 10 scientific books.

Affiliations and expertise

Professor of Psychiatry at the McGovern Medical School, The University of Texas Health Science Center at Houston, TX, USA

Andre Ferrer Carvalho

André F Carvalho is associate professor at the Department of Psychiatry at the University of Toronto and a clinician scientist at the Centre for Addiction and Mental Health (CAMH). He was elected member of the board of councilors of the International Society of Bipolar Disorders (2016-2017) and the vice-chair of the section of private practice psychiatry of the World Psychiatric Association (2015-2017). He sits on the editorial board of several international peer-reviewed journals, including Psychotherapy and Psychosomatics, and has served as a peer reviewer for several leading journals and funding agencies. He is an expert in mood disorders, psychiatric epidemiology, and evidence-based mental health. Dr. Carvalho is a sought after speaker in several national and international meetings, and is the author of over 300 publications.

Affiliations and expertise

Associate Professor, Department of Psychiatry, Temerty Medical School, University of Toronto, Toronto, ON, Canada

Carlos A. Zarate

Dr. Zarate completed his residency training in psychiatry at the Massachusetts Mental Health Center/Brockton VAMC division. He later completed a fellowship in Clinical Psychopharmacology at McLean Hospital of the Consolidated Department of Psychiatry, Harvard Medical School and remained on staff at McLean Hospital as the Director of the Bipolar and Psychotic Disorders Outpatient Services. From 1998 to 2000 Dr. Zarate was the Chief of the Bipolar and Psychotic Disorders Program at the University of Massachusetts Medical School. In 2001, he joined the Mood and Anxiety Disorders Program at NIMH. His achievements and awards include the Ethel-DuPont Warren Award and Livingston Awards, Consolidated Department of Psychiatry, Harvard Medical School; Outstanding Psychiatrist Research Award, Massachusetts Psychiatric Association; Program for Minority Research Training in Psychiatry, APA; the National Alliance for Research on Schizophrenia and Depression Young Investigator Award; National Alliance for Research on Schizophrenia and Depression Independent Investigator Award; the National Institutes of Health Director’s Award Scientific/Medical, the 2011 Brain & Behavior Research Foundation Award for Bipolar Mood Disorder Research, the 2013 National Institute of Health Director’s Award—Scientific/Medical Achievement and Mogens Schou Research Award: Bipolar Disorder and the Simon-Bolivar Award American Psychiatric Association; 2015 Ruth L. Kirschtein Mentoring Award NIH and the Astute Clinician Lecture Award, NIH; the 2019 ACNP Dolores Shockley Minority Mentoring Award; and in 2019 was promoted to NIH Distinguished Investigator, NIMH, NIH. Dr. Zarate is a fellow of the American College of Neuropsychopharmacology and member of the Society of Biological Psychiatry and the Society for Neuroscience. Dr. Zarate’s research focuses on the pathophysiology and development of novel therapeutics for treatment-resistant mood disorders as well as the study of biomarkers and neural correlates of treatment response.

Affiliations and expertise

Chief, Experimental and Therapeutics Branch/Section on Neurobiology and Treatment of Mood and Anxiety Disorders, and Clinical Professor of Psychiatry and Behavioral Sciences, George Washington University, USA